NextCure (NASDAQ:NXTC) Major Shareholder Adar1 Capital Management, Llc Buys 6,400 Shares

NextCure, Inc. (NASDAQ:NXTC) major shareholder Adar1 Capital Management, Llc bought 6,400 shares of NextCure stock in a transaction on Tuesday, July 28th. The shares were bought at an average cost of $4.95 per share, with a total value of $31,680.00. Following the acquisition, the insider directly owned 389,856 shares in the company, valued at approximately $1,929,787.20. This represents a 1.67% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Wednesday, July 29th, Adar1 Capital Management, Llc purchased 3,410 shares of NextCure stock. The shares were bought at an average price of $5.00 per share, for a total transaction of $17,050.00.
• On Monday, July 27th, Adar1 Capital Management, Llc purchased 7,798 shares of NextCure stock. The stock was purchased at an average cost of $5.00 per share, for a total transaction of $38,990.00.

NextCure Trading Down 7.4%

Shares of NextCure stock traded down $0.40 on Wednesday, reaching $5.02. The stock had a trading volume of 355,456 shares, compared to its average volume of 939,730. The business’s 50 day moving average is $3.76 and its two-hundred day moving average is $8.83. NextCure, Inc. has a 1 year low of $1.55 and a 1 year high of $15.74. The company has a market cap of $18.12 million, a P/E ratio of -0.29 and a beta of 1.42.

NextCure (NASDAQ:NXTC) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($1.87) EPS for the quarter, beating the consensus estimate of ($2.10) by $0.23. On average, equities analysts anticipate that NextCure, Inc. will post -7.89 EPS for the current fiscal year.

Analyst Ratings Changes

NXTC has been the subject of several research analyst reports. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of NextCure in a research note on Wednesday, July 15th. Zacks Research upgraded NextCure from a “strong sell” rating to a “hold” rating in a research note on Thursday, June 11th. Weiss Ratings downgraded NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 7th. Finally, Wall Street Zen cut shares of NextCure from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, NextCure has an average rating of “Hold” and an average target price of $19.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Cable Car Capital LP increased its stake in NextCure by 13.1% in the second quarter. Cable Car Capital LP now owns 758,141 shares of the company’s stock valued at $349,000 after acquiring an additional 88,040 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of NextCure by 18.6% in the 4th quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock worth $329,000 after purchasing an additional 3,636 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of NextCure by 18.7% in the 4th quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock worth $477,000 after purchasing an additional 5,300 shares in the last quarter. Exome Asset Management LLC bought a new position in shares of NextCure during the 4th quarter valued at about $2,341,000. Finally, AWM Investment Company Inc. bought a new position in shares of NextCure during the 4th quarter valued at about $1,665,000. 42.65% of the stock is currently owned by hedge funds and other institutional investors.

NextCure Company Profile

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.